Silver Book Fact

Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by 5% to 6%.

Black, Dennis M. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM. 2007; 356(18): 1809-22. http://content.nejm.org/cgi/content/abstract/356/18/1809

Reference

Title
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Publication
NEJM
Publication Date
2007
Authors
Black, Dennis M. et al.
Volume & Issue
Volume 356, Issue 18
Pages
1809-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…